Cartesian Therapeutics Announces New Employment Inducement Grant
Cartesian Therapeutics (NASDAQ: RNAC) announced an employment inducement grant for one new employee on Oct 2, 2025. The company issued an option for 9,700 shares with an exercise price of $10.34 (Nasdaq close on grant date). The option was approved by the board and granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement award.
The option vests 25% on Oct 2, 2026, then in three equal annual installments, becoming fully vested on Oct 2, 2029, and carries a 10-year term.
Cartesian Therapeutics (NASDAQ: RNAC) ha annunciato un grant di induzione all'impiego per un nuovo dipendente il 2 ottobre 2025. L'azienda ha emesso un'opzione per 9.700 azioni con un prezzo di esercizio di $10,34 (chiusura Nasdaq al momento del grant). L'opzione è stata approvata dal consiglio ed è stata concessa ai sensi della Rule 5635(c)(4) delle Nasdaq Listing Rules come premio di induzione.
L'opzione matura per il 25% il 2 ottobre 2026, poi in tre rate annuali uguali, diventando completamente matura il 2 ottobre 2029, e ha una durata di 10 anni.
Cartesian Therapeutics (NASDAQ: RNAC) anunció un otorgamiento por inducción de empleo para un nuevo empleado el 2 de octubre de 2025. La compañía emitió una opción por 9.700 acciones con un precio de ejercicio de $10,34 (cierre de Nasdaq en la fecha de la concesión). La opción fue aprobada por la junta y otorgada conforme a la Regla 5635(c)(4) de las Nasdaq Listing Rules como una recompensa por inducción.
La opción se confiere en un 25% el 2 de octubre de 2026, luego en tres cuotas anuales iguales, quedando plenamente adquirida el 2 de octubre de 2029, y tiene una duración de 10 años.
Cartesian Therapeutics (NASDAQ: RNAC)은 2025년 10월 2일에 한 명의 신규 직원에 대한 고용 유인 부여를 발표했습니다. 회사는 9,700주의 옵션을 발행했고 행사 가격은 $10.34 (Grant일 Nasdaq 마감가)입니다. 이 옵션은 이사회에서 승인되었으며 Nasdaq 상장 규칙의 Rule 5635(c)(4)에 따라 유인 보상으로 부여되었습니다.
이 옵션은 2026년 10월 2일에 25%가 vesting 되고, 이후 매년 같은 금액의 3회에 걸쳐 vesting되며 2029년 10월 2일에 전액 vesting이 되며, 유효 기간 10년를 가집니다.
Cartesian Therapeutics (NASDAQ: RNAC) a annoncé une dotation d'incitation à l'emploi pour un nouvel employé le 2 octobre 2025. Société a émis une option pour 9 700 actions avec un prix d'exercice de $10,34 (clôture Nasdaq à la date de la subvention). L'option a été approuvée par le conseil et accordée en vertu de la Règle 5635(c)(4) des Nasdaq Listing Rules en tant que récompense d'incitation.
L'option se vest à 25% le 2 octobre 2026, puis en trois versements annuels égaux, devenant entièrement acquise le 2 octobre 2029, et elle a une durée de 10 ans.
Cartesian Therapeutics (NASDAQ: RNAC) kündigte am 2. Oktober 2025 eine Beschäftigungsanreize-Zuwendung für einen neuen Mitarbeiter an. Das Unternehmen stellte eine Option über 9.700 Aktien mit einem Ausübungspreis von $10,34 (Nasdaq-Schlusskurs am Grant-Tag) aus. Die Option wurde vom Vorstand genehmigt und gemäß der Rule 5635(c)(4) der Nasdaq Listing Rules als Anreizpreis gewährt.
Die Option vestet zu 25% am 2. Oktober 2026, dann in drei gleichen jährlichen Raten und wird am 2. Oktober 2029 vollständig vestet, und sie hat eine Laufzeit von 10 Jahren.
Cartesian Therapeutics (NASDAQ: RNAC) أعلنت عن منحة تحفيز توظيف لموظف جديد واحد في 2 أكتوبر 2025. أصدرت الشركة خياراً لـ 9,700 سهم بسعر إتمام قدره $10.34 (إغلاق Nasdaq في تاريخ المنحة). تم اعتماد الخيار من قبل المجلس ومنحه وفقاً للوضع Rule 5635(c)(4) من قواعد إدراج Nasdaq كجائزة تحفيزية.
يتناقص الخيار بنسبة 25% في 2 أكتوبر 2026، ثم على ثلاث دفعات سنوية متساوية، ليصبح كاملاً التملك في 2 أكتوبر 2029، ويبلغ مدة عشرة أعوام.
Cartesian Therapeutics (NASDAQ: RNAC) 于 2025 年 10 月 2 日宣布为一名新员工提供一项 就业诱导性授予。公司发放了价值 9,700 股、行使价为 $10.34（授予日 Nasdaq 收盘价）的期权。该期权经董事会批准，并根据 Nasdaq Listing Rules 的 Rule 5635(c)(4) 作为诱导性奖励授予。
该期权将于 2026 年 10 月 2 日一次性归属 25%，随后分三次以同等年度分期归属，直到 2029 年 10 月 2 日 全部归属，且有效期为 10 年。
- None.
- None.
FREDERICK, Md., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of an inducement award to one new employee. On October 2, 2025, the Company issued to this employee an option to purchase an aggregate of 9,700 shares of the Company’s common stock with an exercise price of
About Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA CAR-T currently being evaluated in a Phase 1 trial in patients with multiple myeloma. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X, formerly known as Twitter.
Contact Information:
Investor Contact:
Megan LeDuc
Associate Director, Investor Relations
megan.leduc@cartesiantx.com
Media Contact:
David Rosen
Argot Partners
david.rosen@argotpartners.com
FAQ
What did Cartesian Therapeutics announce on Oct 3, 2025 regarding RNAC stock?
What is the exercise price and grant date for the RNAC inducement option?
How does the RNAC option vest and when is it fully vested?
What is the term length of the RNAC inducement option?
Under what Nasdaq rule was the Cartesian RNAC option granted?
Will the RNAC inducement option immediately dilute existing shareholders?
